Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors
A Allegra, E Sant'Antonio, G Penna… - European journal of …, 2011 - Wiley Online Library
Despite advances in understanding the molecular pathogenesis of multiple myeloma and
promising new therapies, almost all patients eventually relapse with resistant disease. There …
promising new therapies, almost all patients eventually relapse with resistant disease. There …
Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010
S Messaoudi, JF Peyrat, JD Brion… - Expert opinion on …, 2011 - Taylor & Francis
Introduction: Heat-shock protein 90 (Hsp90) is a validated novel anticancer target with
unique features. As a molecular chaperone, Hsp90 is implicated in maintaining the …
unique features. As a molecular chaperone, Hsp90 is implicated in maintaining the …
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
CM Annunziata, L Hernandez, RE Davis… - Blood, The Journal …, 2011 - ashpublications.org
Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in
cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic …
cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic …
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma
V Cheriyath, MA Kuhns, ME Kalaycio… - British journal of …, 2011 - nature.com
Background: Although inhibitors of histone deacetylase inhibitors (HDACis) in combination
with genotoxins potentiate apoptosis, the role of proteases other than caspases in this …
with genotoxins potentiate apoptosis, the role of proteases other than caspases in this …
Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's macroglobulinemia
JY Sun, L Xu, H Tseng, B Ciccarelli, M Fulciniti… - … Myeloma and Leukemia, 2011 - Elsevier
We studied the role of histone deacetylase inhibitors in Waldenstrom's macroglobulinemia
(WM). Gene expression profiling of bone marrow CD19+ cells from 30 patients and 10 …
(WM). Gene expression profiling of bone marrow CD19+ cells from 30 patients and 10 …
Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134
SB Liang, XZ Yang, Y Trieu, Z Li, J Zive… - Clinical cancer …, 2011 - AACR
Purpose: Therapeutic strategies that target insulin-like growth factor 1 receptor (IGF-1R) hold
promise in a wide variety of cancers including multiple myeloma (MM). In this study, we …
promise in a wide variety of cancers including multiple myeloma (MM). In this study, we …
Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in …
JY Sun, H Tseng, L Xu, Z Hunter, B Ciccarelli… - Leukemia & …, 2011 - Taylor & Francis
Histone deacetylases (HDACs) are aberrantly expressed, and inhibitors of HDACs induce
apoptosis in lymphoplasmacytic cells (LPCs) in Waldenström macroglobulinemia (WM). The …
apoptosis in lymphoplasmacytic cells (LPCs) in Waldenström macroglobulinemia (WM). The …
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
M Ooi - 2011 - doras.dcu.ie
The focus of this thesis was to evaluate the mechanisms whereby myeloma cells develop
intrinsic resistance with a focus on resistance in the context of bortezomib treatment. The …
intrinsic resistance with a focus on resistance in the context of bortezomib treatment. The …
Hitzeschockprotein 90-Inhibitoren beim multiplen Myelom
B Lamottke - 2011 - refubium.fu-berlin.de
Beim multiplen Myelom handelt es sich um eine Neoplasie terminal differenzierter B-
Lymphozyten, die durch eine diffuse oder multilokuläre Infiltration des Knochenmarks mit …
Lymphozyten, die durch eine diffuse oder multilokuläre Infiltration des Knochenmarks mit …
[PDF][PDF] Therapy of Multiple Myeloma and Myeloma-Related Kidney Disease. SM J Nephrol Therap. 2017; 2 (1): 1009
O Fuchs - 2011 - researchgate.net
Multiple Myeloma (MM) is a clonal expansion of plasma cells. MM is characterized by
proliferation of malignant clones producing defective monoclonal immunoglobulins in the …
proliferation of malignant clones producing defective monoclonal immunoglobulins in the …